ADOPT Phase 4 Interim Analysis: Avatrombopag in Chronic ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”ADOPT Phase 4 interim analysis: Avatrombopag in chronic ITP
Pleased to share this ASH poster as one of the co-authors. The interim dataset provides useful real-world evidence on avarombopag efficacy and safety in clinical practice.
Study overview:
– 199 patients | Mean 9.7 years from ITP diagnosis to enrollment
– 52.3 weeks median avarombopag dosing duration
– 44.1 cumulative weeks with platelet counts ≥30×10⁹/L
– 59.3% had received prior TPO-RA therapy—reflecting a population with established disease
Health-related quality of life outcomes:
→ EQ-5D-5L: improvements in mobility, usual activities, and pain/discomfort from enrollment to month 12
→ FACIT-Fatigue scores: consistent improvement across follow-up
→ WPAI: measurable reductions in work absenteeism, presenteeism, and overall impairment
→ ITP-PAQ: higher scores at month 12 across multiple scales
Safety findings:
18.1% adverse event rate | 12.6% serious AEs | 5.5% treatment-related AEs | 2.0% discontinued due to AEs
The data demonstrates sustained platelet control alongside functional improvements in work and daily activities. This aligns with our broader understanding of how effective haemostatic management translates to patient-reported outcomes.
The full analysis continues. Worth reviewing if you’re managing patients on TPO-RA therapy or evaluating treatment efficacy beyond platelet counts alone. ”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies